PTCT
NASDAQPTC Therapeutics Inc.
Price$70.94+6.72 (+10.46%)
2026-03-042026-06-05
News · 26 weeks98-80%
2025-12-142026-06-07
Mix3290d
- Insider11(34%)
- SEC Filings8(25%)
- Other5(16%)
- Earnings4(13%)
- Analyst3(9%)
- Leadership1(3%)
Latest news
25 items- SECPTC Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- ANALYSTPTC Therapeutics upgraded by Jefferies with a new price targetJefferies upgraded PTC Therapeutics from Hold to Buy and set a new price target of $85.00
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott sold $202,958 worth of shares (2,812 units at $72.18) as part of a pre-agreed trading plan and exercised 2,812 shares at a strike of $25.69 (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Klein Matthew B. sold $917,154 worth of shares (12,572 units at $72.95) and was granted 12,500 shares, decreasing direct ownership by 0.02% to 393,998 units (SEC Form 4) to satisfy tax liability4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PTC Therapeutics Inc.SCHEDULE 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott exercised 3,540 shares at a strike of $46.54 and sold $279,570 worth of shares (3,540 units at $78.97) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- ANALYSTPTC Therapeutics upgraded by TD Cowen with a new price targetTD Cowen upgraded PTC Therapeutics from Hold to Buy and set a new price target of $90.00
- SECSEC Form 10-Q filed by PTC Therapeutics Inc.10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise – – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback –WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and fi
- PRPTC Therapeutics to Participate in Upcoming Investor ConferencesWARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health Care Conference 2026Tuesday, May 12 at 8:40 a.m. PDT / 11:40 a.m. EDTRBC Capital Markets 2026 Global Healthcare ConferenceWednesday, May 20 at 10 a.m. EDTGoldman Sachs 47th Annual Global Healthcare ConferenceTuesday, June 9 at 9:20 a.m. EDTThe presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.co
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -- Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam -- PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET - WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to a
- PRPTC Therapeutics to Report Results from PIVOT-HD Long Term Extension StudyWARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam. PTC's partner Novartis stated on its quarterly earnings call today that long-term extension data are supportive of the now-initiated Novartis Phase 3 INVEST-HD study and Novartis and PTC will assess potential best next steps for the program including further actions with FDA. To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available
- INSIDERCHIEF EXECUTIVE OFFICER Klein Matthew B. sold $202,094 worth of shares (2,850 units at $70.91), decreasing direct ownership by 0.72% to 394,070 units (SEC Form 4) to satisfy withholding tax4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- PRPTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026WARREN, N.J., April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, May 7, 2026, at 4:30 p.m. ET. To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to r
- SECSEC Form DEFA14A filed by PTC Therapeutics Inc.DEFA14A - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- SECSEC Form DEF 14A filed by PTC Therapeutics Inc.DEF 14A - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation. The inducement grant was approved by PTC's Compensation Committee o
- ANALYSTRaymond James initiated coverage on PTC Therapeutics with a new price targetRaymond James initiated coverage of PTC Therapeutics with a rating of Outperform and set a new price target of $108.00
- INSIDERSEC Form 4 filed by Boulding Mark Elliott4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERSEC Form 4 filed by Golden Lee Scott4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERSEC Form 4 filed by Almstead Neil Gregory4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECSEC Form 144 filed by PTC Therapeutics Inc.144 - PTC THERAPEUTICS, INC. (0001070081) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PTC Therapeutics Inc.SCHEDULE 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)
PTCT FAQ
7 questionsWhat does PTC Therapeutics Inc. do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States...Where does PTCT stock trade?
PTC Therapeutics Inc. (PTCT) is listed on NASDAQ.What sector and industry is PTCT in?
PTC Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PTC Therapeutics Inc. go public?
PTC Therapeutics Inc. (PTCT) completed its IPO in 2013.What are analysts saying about PTCT?
PTC Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-05-27.What companies are similar to PTCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PTCT side-by-side with any of them on Quantisnow.How can I track PTCT on Quantisnow?
Quantisnow aggregates PTC Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTCT to receive live email and push alerts on every new disclosure.